Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1
JC Ricarte-Filho, M Ryder, DA Chitale, M Rivera… - Cancer research, 2009 - AACR
Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC),
and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality …
and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality …
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases
MM Sabra, JM Dominguez, RK Grewal… - The Journal of …, 2013 - academic.oup.com
Background: Radioiodine (RAI) remains the mainstay of therapy for RAI-avid (RAIA) distant
metastatic thyroid carcinoma. We previously demonstrated that RAI-refractory distant …
metastatic thyroid carcinoma. We previously demonstrated that RAI-refractory distant …
Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies
Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients
T Pappa, S Ahmadi, E Marqusee, HL Johnson… - Clinical Cancer …, 2021 - AACR
Purpose: The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease
M Melo, A Gaspar da Rocha, R Batista… - The Journal of …, 2017 - academic.oup.com
Context Little is known about the frequency of key mutations in thyroid cancer metastases
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …
Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy
Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We
aimed to identify genomic and transcriptomic factors associated with structural responses to …
aimed to identify genomic and transcriptomic factors associated with structural responses to …
The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer
J Cao, X Zhu, Y Sun, X Li, C Yun, W Zhang - European Journal of Nuclear …, 2022 - Springer
Abstract Objective The BRAF V600E and TERT promoter mutations are well known to be
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …
BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma
AM Costa, A Herrero, MF Fresno… - Clinical …, 2008 - Wiley Online Library
Summary Purpose BRAF V600E mutation represents the most common oncogenic event in
sporadic papillary thyroid cancer (PTC). There are, however, significant discrepancies …
sporadic papillary thyroid cancer (PTC). There are, however, significant discrepancies …
BRAF mutations in thyroid cancer
The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …
The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer
BRAF V600E and TERT promoter mutations, particularly their genetic duet, are well known
to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of …
to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of …
相关搜索
- thyroid cancers mutational profile
- braf mutations in thyroid cancer
- differentiated thyroid cancers
- papillary thyroid cancer patients
- thyroid cancer metastatic disease
- primary thyroid cancer
- thyroid cancer braf v600e
- thyroid cancers molecular profile
- thyroid cancers iodine therapy
- thyroid cancers distant metastases
- thyroid cancer genetic duet
- thyroid cancers exceptional responses
- thyroid cancer prognostic utility
- thyroid cancer radioiodine therapy
- thyroid cancer molecular basis
- thyroid cancers clinical outcomes